| Event | Date |
|---|---|
| Open Date | 05-06-2026 , Friday |
| Close Date | 09-06-2026 , Tuesday |
| Tentative Allotment | 10-06-2026 , Wednesday |
| Tentative Listing Date | 12-06-2026 , Friday |
| Retail Appl. Cut Off Time | 09-06-2026 , Tuesday 05:00 PM |
| Non Retail Appl. Cut Off Time | 09-06-2026 , Tuesday 04:00 PM |
| Anchor Allotment | 04-06-2026 , Thursday |
| Initiation Of Refund | 11-06-2026 , Thursday |
| Credit Of Share To Demat | 11-06-2026 , Thursday |
Business overview, IPORupee business insight and investor education based on the Red Herring Prospectus dated May 25, 2026.
Hexagon Nutrition Limited is a Mumbai-based nutrition company incorporated in 1993. The company started as a micronutrient formulations player and later expanded into branded wellness nutrition, clinical nutrition and therapeutic nutrition products. Its registered and corporate office is located at Andheri West, Mumbai, Maharashtra.
The company operates in the nutrition and wellness space with a product portfolio across three major segments: branded wellness nutrition and clinical nutrition products, premix formulations, and therapeutic nutrition products such as ready-to-use foods and micronutrient powders.
The company has developed brands such as PENTASURE, OBESIGO, PEDIAGOLD and NUTRONE. Its products have been exported to more than 75 countries during the nine-month period ended December 31, 2025 and the previous three fiscals.
This is the company’s B2C segment. Hexagon Nutrition offers wellness and clinical nutrition products for different age groups, from pediatric to geriatric population.
Key brands include PENTASURE, OBESIGO, PEDIAGOLD and NUTRONE.
This is the company’s B2B2C segment and the largest revenue contributor. The company supplies customised vitamin and mineral premixes to Indian and multinational FMCG companies.
These premixes are used in malted health beverages, biscuits, dairy products, spreads, flour, edible oils, snacks and health supplements.
This is the company’s ESG-focused segment. It includes ready-to-use foods and micronutrient powders.
Ready-to-use therapeutic food is used for severe acute malnutrition, while ready-to-use supplementary food is used for moderate acute malnutrition.
The company serves FMCG companies, public health agencies, global organisations, distributors and development bodies. Exports are a major part of the company’s revenue base.
Hexagon Nutrition operates three manufacturing facilities in India and one international manufacturing facility. These facilities support premix, clinical nutrition, therapeutic nutrition and micronutrient powder products.
| Facility | Location | Main Purpose |
|---|---|---|
| Nashik Facility | Maharashtra | Premix dry and oil premix, wellness and clinical nutrition, RUF and MNP |
| Chennai Facility | Tamil Nadu | Dry powder premix, oil premix and micronutrients |
| Thoothukudi Facility | Tamil Nadu | RUF products |
| Uzbekistan Facility | Tashkent, Uzbekistan | Dry powder premix |
The Chennai and Thoothukudi facilities are located in SEZ zones, which can support export-oriented operations and access to duty-free imports. The company’s facilities have certifications and accreditations such as FSSC 22000, GMP, ISO 9001:2015 and Halal certification.
Hexagon Nutrition Limited IPO is a 100% book-built offer. The IPO is entirely an Offer for Sale. Since there is no fresh issue, the company will not receive proceeds from the IPO. The proceeds will go to the selling shareholders.
| Particulars | Details |
|---|---|
| IPO Type | Offer for Sale |
| Fresh Issue | Not Applicable |
| Offer for Sale | Up to 30,859,704 equity shares |
| Face Value | Rs. 1 per equity share |
| Listing | BSE and NSE |
| Designated Stock Exchange | NSE |
| Registrar | KFin Technologies Limited |
| Anchor Investor Bidding Date | June 4, 2026 |
| Bid Opens | June 5, 2026 |
| Bid Closes | June 9, 2026 |
| Selling Shareholder | Type | Equity Shares Offered |
|---|---|---|
| Arun Purushottam Kelkar | Promoter Selling Shareholder | 1,536,477 |
| Subhash Purushottam Kelkar | Promoter Selling Shareholder | 24,188,993 |
| Aditya Kelkar | Promoter Selling Shareholder | 1,526,092 |
| Nutan Subhash Kelkar | Promoter Group Selling Shareholder | 3,608,142 |
| Segment | 9M FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Premix Formulations | Rs. 1,377.26 million | Rs. 1,546.95 million | Rs. 1,333.13 million | Rs. 1,527.99 million |
| Branded Nutrition and Clinical Nutrition | Rs. 811.93 million | Rs. 920.94 million | Rs. 710.65 million | Rs. 626.99 million |
| Therapeutic Nutrition, RUF and MNP | Rs. 479.76 million | Rs. 778.44 million | Rs. 930.74 million | Rs. 627.83 million |
| Other Revenue | Rs. 6.92 million | Rs. 2.95 million | Rs. 2.79 million | Rs. 2.20 million |
| Total Revenue from Operations | Rs. 2,675.87 million | Rs. 3,249.29 million | Rs. 2,977.31 million | Rs. 2,785.01 million |
The premix formulation segment contributed 51.47% of revenue from operations in 9M FY2026 and 47.61% in FY2025. This shows that the company is significantly dependent on the premix business.
| Particulars | 9M FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Net Sales | Rs. 2,676 million | Rs. 3,249 million | Rs. 2,977 million | Rs. 2,785 million |
| EBITDA | Rs. 376 million | Rs. 401 million | Rs. 249 million | Rs. 172 million |
| EBITDA Margin | 14.0% | 12.3% | 8.4% | 6.2% |
| Net Profit | Rs. 270 million | Rs. 244 million | Rs. 122 million | Rs. 58 million |
| Net Profit Margin | 10.1% | 7.5% | 4.1% | 2.0% |
| Debt-to-Equity | 0.2x | 0.1x | 0.2x | 0.3x |
| ROCE | 16.4% | 18.1% | 12.4% | 7.4% |
The company’s financial performance has improved from FY2023 to FY2025. EBITDA margin increased from 6.2% in FY2023 to 12.3% in FY2025, and net profit margin improved from 2.0% in FY2023 to 7.5% in FY2025. For the nine-month period ended December 31, 2025, net profit margin further improved to 10.1%.
Hexagon Nutrition has a strong domestic and international presence. During the nine-month period ended December 31, 2025 and the previous three fiscals, the company exported products to more than 75 countries.
| Particulars | 9M FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue from India | Rs. 1,175.29 million | Rs. 1,256.28 million | Rs. 1,096.46 million | Rs. 1,005.44 million |
| Revenue from Rest of World | Rs. 1,493.66 million | Rs. 1,990.06 million | Rs. 1,878.06 million | Rs. 1,777.37 million |
Revenue from the rest of the world contributed 55.82% in 9M FY2026 and 61.25% in FY2025, showing that exports are a major part of the company’s business.
Hexagon Nutrition is a fully integrated nutrition company with presence across research, product development, manufacturing, quality assurance, regulatory compliance and marketing. This allows the company to manage multiple stages of the nutrition value chain internally.
| Strength | Explanation |
|---|---|
| Integrated nutrition platform | Presence across premixes, branded nutrition, clinical nutrition and therapeutic nutrition. |
| Established brands | PENTASURE, OBESIGO, PEDIAGOLD and NUTRONE. |
| Export presence | Products exported to more than 75 countries. |
| Manufacturing base | Three Indian facilities and one Uzbekistan facility. |
| Quality certifications | FSSC 22000, GMP, ISO 9001:2015 and Halal certifications. |
| Institutional customer base | Serves FMCG companies, public health agencies, global organisations and distributors. |
| Improving profitability | EBITDA margin and net profit margin have improved over recent periods. |
The premix formulation segment is the largest revenue contributor. It contributed 51.47% of revenue in 9M FY2026 and 47.61% in FY2025. Any adverse development in this segment may materially affect the company’s business and financial performance.
The company depends on a limited number of customers. Revenue from the top 10 customers was 41.82% in 9M FY2026, 45.87% in FY2025, 48.83% in FY2024 and 45.65% in FY2023. Loss of key customers or reduction in order volume may impact revenue.
The company does not have long-term contracts with raw material suppliers. It depends on vitamins, minerals, whey protein, protein concentrate, skimmed milk powder, soya protein isolate, palm oil and other inputs. Price volatility or supply disruption can affect margins and production schedules.
The company operates in a sensitive nutrition and health-related category. Any defective, expired, contaminated or non-compliant product can damage reputation and may result in recalls, penalties or customer loss. The RHP mentions past product quality-related incidents, including contamination at the Thoothukudi facility and incorrect selenium dosage in certain MNP batches.
The company’s manufacturing facilities have shown underutilisation across several product categories. In FY2025, capacity utilisation was 31.04% for dry pre-mix, 18.72% for liquid premix, 10.04% for MNP, 28.51% for RUF and 47.01% for clinical nutrition.
The company has a large export business and imports some raw materials. Therefore, it is exposed to foreign exchange fluctuations, trade restrictions, logistics issues, geopolitical risks and country-specific regulatory requirements.
Hexagon Nutrition is not a simple packaged food company. It operates in a specialised nutrition space where science, formulation capability, regulatory compliance and quality control are very important.
The company’s business has three different layers. The first layer is premix formulations, where the company supplies nutrition ingredients and fortification solutions to larger companies and institutions. This segment gives scale but also creates dependency.
The second layer is branded nutrition, where brands like PENTASURE, OBESIGO and PEDIAGOLD can create direct market recognition. This segment may offer better brand value over the long term if distribution, doctor acceptance, hospital acceptance and consumer trust improve.
The third layer is therapeutic nutrition, where the company supplies products for malnutrition and public health programmes. This segment can create institutional demand, but it is also dependent on tenders, quality standards and global agency procurement cycles.
From IPORupee’s view, the company has a specialised business model, improving margins and a global footprint. However, investors should not ignore the risks. The IPO is entirely an Offer for Sale, which means no fresh funds will come into the company. The company also has customer concentration, segment concentration, export exposure, product quality risk and underutilised capacity.
The most important point for retail investors is valuation. A good company at an expensive valuation may not give good listing or long-term returns. Investors should compare the final price band with revenue growth, margin improvement, ROCE, debt level, peer valuation and QIB demand before taking a decision.
A nutrition company makes products that support health, wellness, clinical nutrition or nutritional deficiencies. These products may include protein powders, disease-specific nutrition products, vitamin and mineral premixes, fortified food ingredients and therapeutic nutrition products.
Premix formulation means a customized blend of vitamins, minerals and other nutrients. These blends are added into food and beverage products to improve their nutritional value.
For example, a food company may add a vitamin and mineral premix into biscuits, milk powder, health drinks, flour or edible oil.
B2C means Business-to-Consumer. In Hexagon Nutrition’s case, branded products such as PENTASURE, OBESIGO and PEDIAGOLD are sold to consumers through offline and online channels.
B2B2C means Business-to-Business-to-Consumer. Hexagon Nutrition sells premixes to another company, and that company uses the premix in its own consumer product.
Therapeutic nutrition refers to nutrition products used for special health needs. These products can support patients, children with malnutrition, pregnant and lactating women or people with specific medical nutrition requirements.
In an Offer for Sale, existing shareholders sell their shares to the public. The money goes to the selling shareholders, not to the company.
In Hexagon Nutrition IPO, there is no fresh issue. Therefore, the IPO will not directly bring new capital into the company for expansion, debt reduction or working capital.
Hexagon Nutrition Limited is a specialised nutrition company with a diversified product portfolio across premix formulations, branded nutrition and therapeutic nutrition. The company has improving margins, established brands, export presence and manufacturing capabilities across India and Uzbekistan.
However, the IPO is fully an Offer for Sale, so no fresh money will come into the company. The business also carries risks related to quality compliance, customer concentration, export dependence, raw material sourcing and underutilised capacity.
For retail investors, this IPO should be studied as a specialised nutrition and healthcare-linked business, not as a normal FMCG IPO. The final decision should depend heavily on valuation, QIB demand, financial sustainability and risk comfort.
This article is for educational and informational purposes only. It is not a recommendation to apply, buy, sell or hold any securities. IPO investments are subject to market risk, business risk and valuation risk. Investors should read the RHP, consult their financial advisor and make their own decision before investing. We are not SEBI registered investment advisors.
| Category | Percentage | No. of Shares Offered | Amount |
|---|---|---|---|
QIB | 50.00 % | 1,54,29,852 | 69.43 Cr |
Retail | 35.00 % | 1,08,00,897 | 48.60 Cr |
Total HNI | 15.00 % | 46,28,955 | 20.83 Cr |
SHNI | 5.00 % | 15,42,985 | 6.94 Cr |
BHNI | 10.00 % | 30,85,970 | 13.89 Cr |
| Application | Discount | Qty (Lot) | Total |
|---|---|---|---|
Retail MIN | - | 333 (1) | ₹ 14,985 |
Retail MAX | - | 4329 (13) | ₹ 1,94,805 |
SHNI MIN | - | 4662 (14) | ₹ 2,09,790 |
SHNI MAX | - | 21978 (66) | ₹ 9,89,010 |
BHNI MIN | - | 22311 (67) | ₹ 10,03,995 |
| Particulars | December 31, 2025 | March 31, 2025 | March 31, 2024 | March 31, 2023 |
|---|---|---|---|---|
Revenue from Operations | 267.59 | 324.93 | 297.73 | 278.50 |
Other Income | 7.98 | 6.36 | 6.89 | 3.15 |
Total Income | 275.57 | 331.29 | 304.62 | 281.65 |
Total Expenses | 239.83 | 296.78 | 285.48 | 267.02 |
Profit Before Exceptional Items and Tax | 35.75 | 34.51 | 19.14 | 14.63 |
Profit Before Tax | 35.75 | 33.72 | 19.50 | 9.42 |
Tax Expenses | 8.72 | 9.34 | 7.29 | 3.60 |
Net Profit | 27.03 | 24.38 | 12.21 | 5.82 |
Basic EPS In Rs. | 2.44 | 1.75 | 1.10 | 0.51 |
Diluted EPS In Rs. | 2.20 | 1.75 | 0.99 | 0.47 |
| Particulars | December 31, 2025 | March 31, 2025 | March 31, 2024 | March 31, 2023 |
|---|---|---|---|---|
Property, Plant and Equipment | 60.71 | 62.18 | 63.17 | 54.28 |
Capital Work-in-progress | 3.86 | 3.37 | 2.30 | 4.11 |
Right of use Assets | 1.88 | 1.99 | 1.77 | 2.04 |
Intangible Assets | 0.67 | 0.09 | 0.12 | 0.18 |
Intangible Assets Under Development | - | 0.67 | - | - |
Financial Assets | 6.67 | 6.54 | 1.61 | 1.03 |
Deferred Tax Assets (Net) | 2.91 | 2.79 | 2.50 | 2.69 |
Other Non Current Assets | 0.01 | 0.09 | 0.30 | 0.60 |
Total Non Current Assets | 76.70 | 77.72 | 71.87 | 64.93 |
Inventories | 88.91 | 61.21 | 79.38 | 87.52 |
Investments | 32.21 | 33.95 | 18.99 | 30.08 |
Trade Receivables | 82.68 | 59.82 | 48.51 | 74.19 |
Cash and Cash Equivalents | 23.40 | 15.22 | 19.35 | 11.39 |
Bank Balance other than Cash and Cash Equivalents | 1.08 | 4.80 | 4.54 | 10.82 |
Other Financial Assets | 2.51 | 1.52 | 1.60 | 1.76 |
Current Tax Assets (Net) | - | - | 0.23 | 0.93 |
Other Current Assets | 20.11 | 7.13 | 6.07 | 7.29 |
Total Current Assets | 250.90 | 183.64 | 178.67 | 223.97 |
Total Assets | 327.60 | 261.36 | 250.54 | 288.90 |
Equity Share Capital | 11.06 | 11.06 | 11.06 | 11.06 |
Other Equity | 209.88 | 183.12 | 164.81 | 152.02 |
Total Equity | 220.94 | 194.18 | 175.87 | 163.08 |
Borrowings | 6.38 | 7.10 | 8.46 | 3.73 |
Other Financial Liabilities | 2.56 | 2.58 | 2.24 | 2.07 |
Provisions | 5.13 | 4.83 | 4.00 | 3.74 |
Total Non Current Liabilities | 14.07 | 14.51 | 14.70 | 9.54 |
Borrowings | 33.41 | 19.50 | 28.44 | 48.15 |
Trade Payables | 42.56 | 18.84 | 19.65 | 45.26 |
Other Financial Liabilities | 11.82 | 9.86 | 7.93 | 7.58 |
Other Current Liabilities | 3.39 | 3.87 | 3.13 | 14.66 |
Provisions | 0.73 | 0.51 | 0.83 | 0.63 |
Current Tax Liabilities (Net) | 0.69 | 0.09 | - | - |
Total Current Liabilities | 92.59 | 52.66 | 59.97 | 116.28 |
Total Equity and Liabilities | 327.60 | 261.36 | 250.54 | 288.90 |
| Particulars | December 31, 2025 | March 31, 2025 | March 31, 2024 | March 31, 2023 |
|---|---|---|---|---|
Cash Flow From Operating Activities | -4.07 | 37.794 | 23.38 | -0.001 |
Cash Flow From Investing Activities | 1.952 | -22.685 | 3.713 | -18.704 |
Cash Flow From Financing Activities | 10.297 | -19.239 | -19.127 | 6.986 |
Net Cash Flow | 8.179 | -4.13 | 7.966 | -11.719 |
| Objective | No Of Shares | Amount |
|---|---|---|
Offer for Sale | 3,08,59,704 | 138.87 Cr |
| # | Title | Published Date |
|---|---|---|
| 1 | Hexagon Nutrition Limited IPO: Opens on June 5, Price Band, Lot Size, OFS Structure, Business Overview, Risks and IPO Rupee Insight | 03-06-2026 , Wednesday |
| Name | Contact Person | Telephone | Website | |
|---|---|---|---|---|
Cumulative Capital Private Limited | Swapnilsagar Vithalani / Jigar Bhanushali | +91 98196 62664 / 82000 52280 | hnl.ipo@cumulativecapital.group | www.cumulativecapital.group |
Catalyst Capital Partners Private Limited | Kaushik Gandhi | +91 98190 45092 | mb@catalystcapital.in | www.catalystcapital.in |
Understand company details, IPO size, price band, lot size, exchange listing, fresh issue and Offer for Sale (OFS) in simple language for retail investors.
This IPO is of Hexagon Nutrition Ltd. The issue is scheduled to open on Friday, 05 June 2026 and closes on Tuesday, 09 June 2026.
After the IPO process is completed, the shares are proposed to be listed on both NSE and BSE.
IPO size means the total amount offered to investors through the public issue.
For Hexagon Nutrition Ltd IPO, the total issue size is Rs 138.87 crore, consisting of an Offer for Sale (OFS) of Rs 138.87 crore.
Price band is the price range within which investors can bid for shares in a book-built IPO.
For this IPO, the lower price band is Rs 42 per share and the upper price band is Rs 45 per share.
Lot size is the minimum number of shares an investor must apply for in an IPO. IPO applications are usually made in fixed lot multiples.
For Hexagon Nutrition Ltd IPO, the minimum lot size is 333 shares. At the upper price band of Rs 45 per share, the minimum application amount is Rs 14,985. Applications must be made in multiples of 333 shares.
Offer for Sale (OFS) means existing shareholders sell their shares to the public through the IPO.
For Hexagon Nutrition Ltd IPO, the Offer for Sale (OFS) size is Rs 138.87 crore. In an OFS, the selling shareholders receive the money, and the company usually does not receive funds from that portion.
Understand the important IPO dates, allotment process, refund schedule and listing timeline in a retail-friendly format.
The IPO opening date is the first day on which investors can apply for the public issue.
For Hexagon Nutrition Ltd IPO, the IPO opens on Friday, 05 June 2026.
The IPO closing date is the last day on which investors can submit, modify, or cancel their IPO applications.
Hexagon Nutrition Ltd IPO closes on Tuesday, 09 June 2026.
The tentative allotment date is the expected date on which the registrar finalizes the share allotment for valid IPO applications.
For Hexagon Nutrition Ltd IPO, the tentative allotment date is Wednesday, 10 June 2026.
The tentative listing date is the expected date on which IPO shares begin trading on the stock exchanges.
Hexagon Nutrition Ltd IPO is expected to list on Friday, 12 June 2026.
After allotment, funds are unblocked or refunds are initiated for non-allotted investors, while allotted shares are credited to investors' demat accounts before listing.
For Hexagon Nutrition Ltd IPO, refund initiation is expected on Thursday, 11 June 2026, and credit of shares to demat accounts is expected on Thursday, 11 June 2026.
Understand IPO category-wise reservation, QIB quota, retail quota, HNI allocation, shareholder reservation and the meaning of structure columns in a simple format.
IPO structure shows how shares are divided among different categories of investors, such as QIB, Retail, NII/HNI, Employees, and Shareholders.
For Hexagon Nutrition Ltd IPO, the available categories in the structure table include QIB, Retail, Non-Institutional Investors (NII/HNI). The NII/HNI category includes SHNI and BHNI sub-categories. Investors can use this table to understand category-wise allocation before applying.
QIB stands for Qualified Institutional Buyers. This category includes mutual funds, banks, insurance companies, and other large financial institutions.
In Hexagon Nutrition Ltd IPO, 50% shares are reserved under the QIB category, with 1,54,29,852 shares offered, and an allocation amount of ₹69.43 crore.
The Retail category is reserved for individual investors and HUFs applying for up to Rs 2 lakh within the retail investment limit allowed under IPO rules.
In Hexagon Nutrition Ltd IPO, 35% shares are reserved under the Retail category, with 1,08,00,897 shares offered, and an allocation amount of ₹48.60 crore.
NII/HNI stands for Non-Institutional Investors / High Net-Worth Individuals. This category generally includes investors applying for more than Rs 2 lakh, above the retail investment limit.
In Hexagon Nutrition Ltd IPO, 15% shares are reserved under the NII/HNI category, with 46,28,955 shares offered, and an allocation amount of ₹20.83 crore.
SHNI stands for Small HNI. It is a sub-category within the NII/HNI category and generally refers to applications for more than Rs 2 lakh but not exceeding Rs 10 lakh.
In Hexagon Nutrition Ltd IPO, 5% shares are reserved under the SHNI sub-category, with 15,42,985 shares offered, and an allocation amount of ₹6.94 crore.
BHNI stands for Big HNI. It is a sub-category within the NII/HNI category and generally refers to applications for more than Rs 10 lakh.
In Hexagon Nutrition Ltd IPO, 10% shares are reserved under the BHNI sub-category, with 30,85,970 shares offered, and an allocation amount of ₹13.89 crore.
Understand retail lot size, HNI application limits, employee category, shareholder category and investment amount calculations using the IPO lot table.
Lot size is the minimum number of shares an investor must apply for in an IPO. IPO applications are usually made in fixed lot multiples.
For Hexagon Nutrition Ltd IPO, the minimum lot size is 333 shares. At the upper price band of Rs 45 per share, the minimum application amount is Rs 14,985. Applications must be made in multiples of 333 shares.
Retail minimum application shows the minimum application size for retail investors.
For Hexagon Nutrition Ltd IPO, the Retail minimum application is 333 shares (1 lot) for about Rs 14,985.
Retail maximum application shows the maximum application size generally available under the retail category.
For Hexagon Nutrition Ltd IPO, the Retail maximum application is 4,329 shares (13 lots) for about Rs 1,94,805.
SHNI minimum application shows the minimum application size for the Small HNI category.
For Hexagon Nutrition Ltd IPO, the SHNI minimum application is 4,662 shares (14 lots) for about Rs 2,09,790.
SHNI maximum application shows the maximum application size available under the Small HNI category, when provided.
For Hexagon Nutrition Ltd IPO, the SHNI maximum application is 21,978 shares (66 lots) for about Rs 9,89,010.
BHNI minimum application shows the minimum application size for the Big HNI category.
For Hexagon Nutrition Ltd IPO, the BHNI minimum application is 22,311 shares (67 lots) for about Rs 10,03,995.
Understand important financial figures in simple language using the financial statement data available for the IPO.
Financial Highlights show important numbers from the company's financial statements. These may include income, expenses, profit, assets, liabilities, cash flow and other financial information, depending on the data available for the IPO.
The table displays available financial data based on the IPO information currently available. Fields may differ from company to company depending on disclosures and reporting format.
Investors should read the table to understand the company's financial performance and financial position over different periods.
The table may help users review income, expenses, profitability, balance sheet position, cash movement or other financial information, depending on the available data.
Financial statement line items may differ because companies operate in different industries and may follow different reporting formats.
Some companies may provide detailed financial breakup, while others may present broader financial categories.
Investors should review income, expenses, profitability, debt position, asset base, liabilities and cash flow position together.
A single financial figure should not be used alone to judge the company.
Profit is important, but it does not show the full financial picture.
Investors should also review revenue quality, expenses, debt, assets, liabilities, cash flow, valuation and business risks.
Cash flow helps investors understand how money moves in and out of the business.
A company may report profit but still face cash flow pressure, so cash flow should be reviewed along with profit, debt and balance sheet information.
No. Financial Highlights are useful, but investors should also review valuation, peer comparison, KPI data, business risks, IPO pricing, management discussion and official offer documents such as the RHP or DRHP.
Understand how the company may be compared with similar businesses using the peer comparison data available for the IPO.
Peer Comparison means comparing the IPO company with businesses operating in a similar sector or industry.
It helps investors understand the company in a broader industry context.
Peer Comparison helps investors understand how the company can be compared with similar businesses using available financial or valuation metrics.
It is useful for context, but it should not be treated as a final investment conclusion.
Peer comparison metrics may differ depending on the companies selected, accounting format, business model and available public information.
Investors should compare only relevant and similar metrics.
Investors should use the peer comparison table as a reference point.
Available metrics should be read together with business model, scale, profitability, margins, debt, growth, valuation and IPO pricing.
No. Peer Comparison does not directly decide whether an IPO is good or bad.
It only provides context for comparison. Final analysis should include financial statements, KPI data, valuation, risk factors and official offer documents.
No. Peer Comparison is only one part of IPO analysis.
Investors should also review financial statements, KPI data, business risks, valuation, IPO pricing and company fundamentals.
Understand important KPI metrics in simple language using the key performance indicator data available for the IPO.
Key Performance Indicators, or KPIs, are financial and valuation metrics used to understand profitability, efficiency, leverage, return-based ratios and earnings performance.
They help investors understand the company beyond basic financial figures.
KPIs help investors assess profitability, capital efficiency, leverage, valuation and earnings quality.
They should be reviewed together with financial statements, peer comparison and IPO pricing.
KPI data may differ depending on the company, industry, financial disclosures and available offer document information.
Not every IPO may provide every KPI, and some metrics may not be applicable to every business.
Investors should read KPI metrics together instead of relying on one ratio.
A single KPI may not give the full picture unless it is reviewed with financial statements, peer comparison, business model and valuation.
No. High or low KPI values need context.
The meaning of a ratio may differ depending on industry, business model, debt level, growth stage, profitability and IPO valuation.
No. KPI data is useful, but it should not be used alone.
Investors should also review financial statements, peer comparison, business risks, valuation, IPO pricing and official offer documents such as the RHP or DRHP.